Interpace Diagnostics' ThyraMIR test has obtained a positive coverage policy decision from Premera Blue Cross as a test for thyroid nodules considered indeterminate by standard cytopathological analysis. The coverage makes the microRNA gene expression classifier available to over 2 million members of the health plan mostly based in Washington, Alaska and Oregon.
Premera Blue Cross to cover use of Interpace's thyroid test
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.